MAIA Biotechnology, Inc. MAIA
1.25 USD +0.24 (+23.76%)
Regular-session close
1.28 +0.03 +2.56%
Pre-market · Nov 18, 8:19 AM ET
1.03 Day range 1.25
0.87 52-week range 3.19
- YTD
- -18.30%
- 1 year
- +23.76%
News
benzinga.com MAIA Biotechnology Announces Updated Interim Efficacy Data From Part C Of Its Phase 2 THIO-101 Expansion Trial Evaluating Ateganosine For Advanced Non-Small Cell Lung Cancer; Observed Disease Control Rate Is 88% Updated interim efficacy data from Part C of its Phase 2 THIO-101 expansion trial evaluating its novel telomere-targeting therapy, ateganosine, as a third-line (3L) treatment for advanced non-small…
globenewswire.com MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer MAIA advances novel telomere-targeting agent under FDA's Fast Track designation Further data from THIO-101 Part C may support accelerated approval filing with FDA CHICAGO, Nov. 17, 2026 (GLOBE…
globenewswire.com Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) New York, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology,…
